IsoPlexis, which provides a single-cell proteomics platform for drug development, raised $125 million by offering 8.3 million shares at $15, the midpoint of the $14 to $16 range. At pricing, the company commands a fully diluted market value of $648 million.
The Branford, CT-based company plans to list on the Nasdaq under the symbol ISO. Morgan Stanley, Cowen, Evercore ISI, and SVB Leerink acted as joint bookrunners on the deal.
